Primary HyperÂparathyroidism: Diagnosis and Surgical Criteria
A step-by-step worksheet for physicians that sorts paired calcium and PTH results, screens for secondary causes and FHH, and applies published criteria for parathyroid surgery.
For physicians reviewing published diagnostic and surgical criteria. This worksheet is general education. It does not diagnose or recommend care for any individual patient, and decisions rest with the patient's own physician. Reference ranges vary by laboratory; enter the local reference limits.
Continue from an earlier summary
Paste the Copyable Summary saved from an earlier session to fill its values back in, then add the results that were missing.
⚠ The worksheet is not running
Results will not update until it starts.
Starting keeps the values already entered. If it cannot start, the button reloads the page, which clears values typed so far; if that does not help, try another browser. The tables and criteria still apply as written.
⚠ The worksheet is still loading
If this does not clear in a few seconds, reload the page. Values typed so far are saved first.
Primary hyperparathyroidism (PHPT) is a biochemical diagnosis: hypercalcemia with a simultaneously elevated or inappropriately non-suppressed PTH, after secondary causes and familial hypocalciuric hypercalcemia (FHH) are excluded. Imaging (sestamibi, ultrasound, 4D-CT) plays no role in diagnosis and is reserved for surgical localization once the biochemistry is confirmed.
Confirm true hypercalcemia
Use an albumin-adjusted total calcium, confirmed on at least two occasions, because calcium in mild PHPT can drift into the normal range. When albumin is below 4.0 g/dL, adjusted Ca = measured Ca + 0.8 × (4.0 − albumin), rounded to 0.1 mg/dL; at 4.0 g/dL or higher, the measured total calcium is used. The formula over-corrects when albumin is below 3.0 g/dL or kidney function is impaired.
Ionized calcium is the gold standard and becomes essential when total calcium is equivocal, albumin is low, or normocalcemic PHPT is suspected; up to 10% of patients with PHPT have a normal total but elevated ionized calcium. When it is entered, it decides whether calcium is high. Values below 2.5 are read as mmol/L.
Pair it with an intact PTH
Draw an intact (second-generation) PTH at the same time as the calcium, given PTH's minutes-long half-life. This pairing is the central branch point.
| Calcium | PTH | Interpretation |
|---|---|---|
| High | High | Classic PHPT (about 80% of cases) |
| High | Inappropriately normal (20 pg/mL or more, not suppressed) | Normohormonal PHPT (up to about 25%) |
| High | Suppressed or low (below 20 pg/mL) | Not PHPT. Consider malignancy, granulomatous disease, vitamin D or A toxicity, medications |
| Normal (total and ionized) | High | Possible normocalcemic PHPT; requires exclusion of all secondary causes |
| Low | High | Not PHPT. Secondary hyperparathyroidism pattern (for example vitamin D deficiency or kidney disease) |
Exclude secondary hyperparathyroidism and mimics
Secondary (physiologic) PTH elevation is distinguished chiefly by normal or low calcium. Common causes are vitamin D deficiency, chronic kidney disease, malabsorption, hypercalciuria and drugs. If an elevated PTH normalizes after vitamin D repletion, the diagnosis is secondary hyperparathyroidism, not PHPT.
Present in this patient?
If an interfering medication can safely be stopped, it is usually stopped and the calcium and PTH are rechecked.
Hypercalciuria (renal calcium leak) criteria. Check the box only if both apply: (1) 24-h urine calcium above 250 mg/day in women or 300 mg/day in men on the usual diet, collected after holding thiazides for at least 1 week, with normal total and ionized calcium and an elevated PTH; and (2) the PTH rise is shown to be secondary to urinary calcium loss: on a thiazide challenge (hydrochlorothiazide 25 mg twice daily for 2 weeks, only if eGFR is 60 or more, then recheck calcium, PTH and potassium), PTH normalizes while calcium stays normal. Calcium that rises above normal with a persistently high PTH favors normocalcemic PHPT, and a PTH that falls but does not normalize is indeterminate. A high urine calcium alone does not qualify, because normocalcemic PHPT can also cause hypercalciuria. The challenge is only modestly accurate (about 82% sensitivity and 78% specificity in one small series).
Helpful 1,25-dihydroxyvitamin D is high or high-normal in PHPT, low in secondary hyperparathyroidism, and useful when granulomatous disease is suspected.
When PTH is suppressed (guided by history and examination): SPEP/UPEP for myeloma; PTHrP, which is high in adenocarcinoma and squamous cancers; 1,25-dihydroxyvitamin D, which is high in granulomatous disease and lymphoma; bone-specific alkaline phosphatase for lytic bone lesions; skeletal, chest, abdominal and pelvic imaging for malignancy; and TSH, cortisol and IGF-1 for other endocrine causes.
Separate PHPT from FHH with the CCCR
Familial hypocalciuric hypercalcemia (FHH) is separated from PHPT with the calcium/creatinine clearance ratio (CCCR). Note that parathyroidectomy cures PHPT but not FHH, which does not need treatment, so FHH is excluded before surgery whenever hypercalcemia is longstanding, mild or familial. Vitamin D deficiency and renal insufficiency both falsely lower the ratio into the FHH range, so vitamin D is repleted first.
If the lab reports only a ratio, enter it here. When the 24-h urine calcium, urine creatinine and serum creatinine are all entered, the CCCR is calculated from them instead.
CCCR = (24-h urine Ca × serum Cr) / (serum Ca × 24-h urine Cr)
| CCCR | Interpretation | Caveat |
|---|---|---|
| Above 0.02 | Supports PHPT; virtually excludes FHH | About 35% of true PHPT falls below 0.02 (low sensitivity) |
| 0.01 to 0.02 | Indeterminate gray zone; genetic testing (CASR, then AP2S1, then GNA11) | |
| Below 0.01 | Suggests FHH | Sensitivity 65–80%, specificity 74–88%; about 20% of FHH have a CCCR above 0.01 |
Where these results point
⚠ The worksheet is not running
Results will not update until it starts.
Starting keeps the values already entered. If it cannot start, the button reloads the page, which clears values typed so far; if that does not help, try another browser. The tables and criteria still apply as written.
Once PHPT is biochemically confirmed, the surgical decision follows one cascade: classic symptomatic disease, then any single objective threshold, then stated subjective symptoms attributable to PHPT. Parathyroidectomy is the only definitive cure. The thresholds combine the Fifth International Workshop (2022) criteria with the AAES 2016 guidelines, and meeting any one is sufficient. Values from Part 1 carry over.
Screen for occult end-organ disease
Before a patient is considered asymptomatic, renal imaging for silent stones or nephrocalcinosis and vertebral imaging for subclinical fractures reclassify a substantial fraction of patients as surgical.
Classic symptomatic disease
Any one of these, attributable to PHPT, makes surgery indicated, with unanimous guideline agreement.
Objective criteria in asymptomatic disease
Any one is sufficient. In normocalcemic PHPT, all criteria apply except the serum calcium threshold.
| Criterion | Threshold | This patient |
|---|---|---|
| Serum calcium Essential | More than 1.0 mg/dL (0.25 mmol/L) above the upper limit of normal | — |
| Age Essential | Younger than 50 | — |
| Bone density Essential | T-score −2.5 or lower at any listed site | — |
| Vertebral fracture Essential | Any, including subclinical | — |
| Kidney function Essential | eGFR below 60 mL/min/1.73 m², or a consistent annual decline of more than 3 trending below 60 | — |
| Renal imaging Essential | Nephrolithiasis or nephrocalcinosis, including subclinical | — |
| 24-h urine calcium Helpful | Above 250 mg/day (women) or 300 mg/day (men) | — |
| Surveillance | Unable or unwilling to comply; surgery preferred (AAES, strong) | — |
| Cardiovascular disease Helpful | Other than hypertension: may be offered (AAES only, weak); not an International Workshop criterion | — |
Stated subjective symptoms
Symptoms the patient reports that are plausibly attributable to PHPT. AAES 2016 and the Australian and New Zealand 2024 guideline support parathyroidectomy for neurocognitive and neuropsychiatric symptoms attributable to PHPT (strong recommendation, low-quality evidence). The Fifth International Workshop does not accept these as formal criteria.
Parathyroidectomy Indication
⚠ The worksheet is not running
Results will not update until it starts.
Starting keeps the values already entered. If it cannot start, the button reloads the page, which clears values typed so far; if that does not help, try another browser. The tables and criteria still apply as written.
Copyable Summary
A summary of the entered values and the results of both parts. It updates as values are entered and can be pasted into a note or message; the main answers stay bold where the note accepts formatting. Pasted into "Continue from an earlier summary" at the top, it fills the worksheet in again.
References
Guidelines, consensus statements, and formal criteria
- Wilhelm SM, Wang TS, Ruan DT, et al. The American Association of Endocrine Surgeons Guidelines for Definitive Management of Primary Hyperparathyroidism. JAMA Surg. 2016.
- Pappachan JM, Lahart IM, Viswanath AK, et al. Parathyroidectomy for adults with primary hyperparathyroidism. Cochrane Database Syst Rev. 2023.
- Milat F, Ramchand SK, Herath M, et al. Primary hyperparathyroidism in adults—(Part I) assessment and medical management: Position statement of the Endocrine Society of Australia, the Australian & New Zealand Endocrine Surgeons, and the Australian & New Zealand Bone and Mineral Society. Clin Endocrinol (Oxf). 2024.
Major reviews and overviews
- Zhu CY, Sturgeon C, Yeh MW. Diagnosis and Management of Primary Hyperparathyroidism. JAMA. 2020.
- Walker MD, Silverberg SJ. Primary hyperparathyroidism. Nat Rev Endocrinol. 2018.
- Bilezikian JP, Bandeira L, Khan A, Cusano NE. Hyperparathyroidism. Lancet. 2018.
- Insogna KL. Primary Hyperparathyroidism. N Engl J Med. 2018.
- Marcocci C, Cetani F. Primary Hyperparathyroidism. N Engl J Med. 2011.
- Bilezikian JP, Silverberg SJ. Asymptomatic Primary Hyperparathyroidism. N Engl J Med. 2004.
- Bilezikian JP, Cusano NE, Khan AA, et al. Primary hyperparathyroidism. Nat Rev Dis Primers. 2016.
- Palermo A, Tabacco G, Makras P, et al. Primary hyperparathyroidism: from guidelines to outpatient clinic. Rev Endocr Metab Disord. 2024.
- Walker MD, Shane E. Hypercalcemia: A Review. JAMA. 2022.
- Htoo STY, Cusano NE. Management of Primary Hyperparathyroidism: Historical and Contemporary Perspectives. Endocr Pract. 2025.
- Medina JE, Randolph GW, Angelos P, et al. Primary hyperparathyroidism: Disease of diverse genetic, symptomatic, and biochemical phenotypes. Head Neck. 2021.
- Amir Sam, Karim Meeran, Neil Hill. Calcium homeostasis, hypercalcaemia, and primary hyperparathyroidism. Endocrinology and Diabetes. 2023. (not indexed in PubMed)
- Markowitz ME, Underland L, Gensure R. Parathyroid Disorders. Pediatr Rev. 2016.
- Han CH, Fry CH, Sharma P, Han TS. A clinical perspective of parathyroid hormone related hypercalcaemia. Rev Endocr Metab Disord. 2020.
- Alore EA, Ramsey DJ, Makris KI. Diagnosis and Management of Hyperparathyroidism—Reply. JAMA Intern Med. 2019.
Biochemical diagnosis, phosphate, magnesium, and vitamin D
- Columbu C, Rendina D, Gennari L, et al. Phosphate metabolism in primary hyperparathyroidism: a real-life long-term study. Endocrine. 2025.
- Düğer H, Uçan B, Çalışkan M, et al. Hypomagnesemia may be associated with symptomatic disease in patients with primary hyperparathyroidism. Endocrine. 2024.
- Al Alawi AM, Majoni SW, Falhammar H. Magnesium and Human Health: Perspectives and Research Directions. Int J Endocrinol. 2018.
- Moosgaard B, Vestergaard P, Heickendorff L, Mosekilde L. Plasma 1,25-dihydroxyvitamin D levels in primary hyperparathyroidism depend on sex, body mass index, plasma phosphate and renal function. Clin Endocrinol (Oxf). 2007.
Familial hypocalciuric hypercalcemia and the CCCR
- Hannan FM, Kallay E, Chang W, Brandi ML, Thakker RV. The calcium-sensing receptor in physiology and in calcitropic and noncalcitropic diseases. Nat Rev Endocrinol. 2018.
- Thakker RV. Genetics of parathyroid tumours. J Intern Med. 2016.
- Asla Q, Sardà H, Seguí N, et al. Clinical and outcome comparison of genetically positive vs. negative patients in a large cohort of suspected familial hypocalciuric hypercalcemia. Endocrine. 2024.
- Christensen SE, Nissen PH, Vestergaard P, et al. Discriminative power of three indices of renal calcium excretion for the distinction between familial hypocalciuric hypercalcaemia and primary hyperparathyroidism: a follow-up study on methods. Clin Endocrinol (Oxf). 2008.
- Shinall MC, Dahir KM, Broome JT. Differentiating Familial Hypocalciuric Hypercalcemia From Primary Hyperparathyroidism. Endocr Pract. 2013.
- Bhangu JS, Selberherr A, Brammen L, Scheuba C, Riss P. Efficacy of calcium excretion and calcium/creatinine clearance ratio in the differential diagnosis of familial hypocalciuric hypercalcemia and primary hyperparathyroidism. Head Neck. 2019.
- Jayasena CN, Mahmud M, Palazzo F, et al. Utility of the urine calcium-to-creatinine ratio to diagnose primary hyperparathyroidism in asymptomatic hypercalcaemic patients with vitamin D deficiency. Ann Clin Biochem. 2011.
- Kaderli RM, Riss P, Geroldinger A, et al. Factors influencing pre-operative urinary calcium excretion in primary hyperparathyroidism. Clin Endocrinol (Oxf). 2017.
Normocalcemic PHPT
- Muñoz de Nova JL, Sampedro-Nuñez M, Huguet-Moreno I, Marazuela Azpiroz M. A practical approach to normocalcemic primary hyperparathyroidism. Endocrine. 2021.
- Dawood NB, Yan KL, Shieh A, et al. Normocalcaemic primary hyperparathyroidism: An update on diagnostic and management challenges. Clin Endocrinol (Oxf). 2020.
- Liu Y, Sinha Gregory N, Andreopoulou P, Kashyap S, Cusano N. Approach to the Patient: Normocalcemic Primary Hyperparathyroidism. J Clin Endocrinol Metab. 2025.
Surgical indications, outcomes, and neuropsychiatric endpoints
- Stephen AE, Mannstadt M, Hodin RA. Indications for Surgical Management of Hyperparathyroidism: A Review. JAMA Surg. 2017.
- Livschitz J, Yen TWF, Evans DB, Wang TS, Dream S. Long-term Quality of Life After Parathyroidectomy for Primary Hyperparathyroidism: A Systematic Review. JAMA Surg. 2022.
- Song Z, Balachandra S, Wu C, et al. Risk of Neuropsychiatric Disorders in Primary Hyperparathyroidism: Parathyroidectomy Versus Nonoperative Management. World J Surg. 2025.
- Chitnis OS, Wagner SK, Caraway JJ, et al. Beck Depression Inventory-II Response Following Parathyroidectomy for Primary Hyperparathyroidism: A Systematic Review and Meta-Analyses. Head Neck. 2025.
- Castellano E, Boriano A, Attanasio R, Borretta G, Pia A. Adoption of the Fifth Workshop Urinary Calcium Threshold in Asymptomatic Primary Hyperparathyroidism. Endocr Pract. 2026.
- Perrier N, Lang BH, Farias LCB, et al. Surgical Aspects of Primary Hyperparathyroidism. J Bone Miner Res. 2022.
Preoperative localization and renal calcium leak
- Petranović Ovčariček P, Giovanella L, Carrió Gasset I, et al. The EANM practice guidelines for parathyroid imaging. Eur J Nucl Med Mol Imaging. 2021.
- Expert Panel on Neurological Imaging; Zander D, Bunch PM, Policeni B, et al. ACR Appropriateness Criteria Parathyroid Adenoma. J Am Coll Radiol. 2021.
- Cusano NE, Cetani F. Normocalcemic primary hyperparathyroidism. Arch Endocrinol Metab. 2022.
- Bollerslev J, Rejnmark L, Zahn A, et al. European Expert Consensus on Practical Management of Specific Aspects of Parathyroid Disorders in Adults and in Pregnancy: Recommendations of the ESE Educational Program of Parathyroid Disorders. Eur J Endocrinol. 2022.
- Eremkina AK, Elfimova AR, Aboisheva EA, et al. The short test with hydrochlorothiazide in differential diagnosis between primary normocalcemic and secondary hyperparathyroidism for inpatient treatment. Probl Endokrinol (Mosk). 2022. (in Russian)
- Verly E, Lapauw B, Verroken C. Evaluation of the Thiazide Challenge Test to Differentiate Primary From Hypercalciuria-Related Hyperparathyroidism. J Clin Endocrinol Metab. 2025.
This page